Colin Bristow
Stock Analyst at UBS
(1.67)
# 3,309
Out of 5,182 analysts
105
Total ratings
40.32%
Success rate
-4.4%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Maintains: Neutral | $4 → $10 | $7.43 | +34.59% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $440.05 | +24.08% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $139.03 | -19.44% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $70.42 | +13.60% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.64 | +37.36% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.75 | -42.86% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $25.12 | -32.32% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $349.82 | -8.81% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.51 | +59.36% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $27.34 | +2.41% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $120.15 | -0.12% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $176.37 | +14.54% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.02 | +1,468.63% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $746.46 | +47.23% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $21.79 | +666.41% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $929.55 | -54.82% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.38 | -82.43% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.95 | +823.08% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $206.47 | -29.29% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $58.06 | +29.18% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.76 | +842.03% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.87 | +84.80% | 1 | Aug 23, 2021 |
enGene Therapeutics
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $7.43
Upside: +34.59%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $440.05
Upside: +24.08%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $139.03
Upside: -19.44%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $70.42
Upside: +13.60%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.64
Upside: +37.36%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.75
Upside: -42.86%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $25.12
Upside: -32.32%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $349.82
Upside: -8.81%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.51
Upside: +59.36%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $27.34
Upside: +2.41%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $120.15
Upside: -0.12%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $176.37
Upside: +14.54%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.02
Upside: +1,468.63%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $746.46
Upside: +47.23%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $21.79
Upside: +666.41%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $929.55
Upside: -54.82%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.38
Upside: -82.43%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.95
Upside: +823.08%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $206.47
Upside: -29.29%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $58.06
Upside: +29.18%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.76
Upside: +842.03%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.87
Upside: +84.80%